Pulmonx Corp

For the period ended Sep 30, 2024. Filed Nov 1, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 1, 2024

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue	$20,387	$17,668	$60,024	$49,397
Cost of goods sold	5,361	4,639	15,613	13,045
Gross profit	15,026	13,029	44,411	36,352
Operating expenses
Research and development	3,744	4,220	13,569	14,184
Selling, general and administrative	25,411	23,985	75,129	70,184
Total operating expenses	29,155	28,205	88,698	84,368
Loss from operations	(14,129)	(15,176)	(44,287)	(48,016)
Interest income	1,269	1,490	4,016	4,027
Interest expense	(891)	(893)	(2,665)	(2,327)
Other (expense) income, net	(201)	(262)	179	(316)
Net loss before tax	(13,952)	(14,841)	(42,757)	(46,632)
Income tax expense	192	59	462	323
Net loss	(14,144)	(14,900)	(43,219)	(46,955)
Other comprehensive income (loss)
Currency translation adjustment	412	(12)	(97)	230
Change in unrealized gains (losses) on marketable securities	149	—	(9)	139
Total other comprehensive income (loss)	561	(12)	(106)	369
Comprehensive loss	$(13,583)	$(14,912)	$(43,325)	$(46,586)
Net loss per share attributable to common stockholders, basic and diluted	$(0.36)	$(0.39)	$(1.11)	$(1.24)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	39,276,447	38,119,824	38,953,032	37,838,822

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.